[Form 4] Supernus Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Frank Mottola, SVP, Quality, GMP, Ops, IT at Supernus Pharmaceuticals (SUPN), reported option exercise and an immediate sale on 08/25/2025. He exercised an employee stock option with a $12.98 exercise price to acquire 14,000 shares and simultaneously sold 14,000 shares at $44.51.

After these transactions the filing shows the Reporting Person beneficially owned 29,496 shares (which includes 345 shares from the company Employee Stock Purchase Plan). The filing also notes the exercised option vests in four equal annual installments beginning March 1, 2017, and that the underlying shares were sold prior to option expiration on March 1, 2026.

Insights

Financial Analyst

TL;DR Insider exercised options at $12.98 and sold the resulting 14,000 shares at $44.51 on 08/25/2025, a routine compensation monetization.

The transaction reflects an exercise-and-sell by a senior executive, converting long‑dated option compensation into shares and realizing proceeds at the reported sale price. The filing discloses continuing beneficial ownership of 29,496 shares, including 345 ESPP shares. This appears to be a personal liquidity event using vested option rights rather than a grant or open‑market accumulation.

Corporate Governance Expert

TL;DR A company officer exercised vested options and sold the shares; disclosure meets Section 16 reporting requirements.

The Form 4 documents exercise of an employee stock option (exercise price $12.98) and an immediate sale of the same number of shares, consistent with routine executive compensation realization. The filing includes required explanations (ESPP shares and vesting schedule) and is signed by an attorney‑in‑fact. There are no disclosures here of unusual transfers, pledges, or related‑party transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mottola Frank

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Quality, GMP, Ops, IT

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		M		14,000	A	$12.98	29,496(1)	D
Common Stock	08/25/2025		S		14,000(2)	D	$44.51	15,496	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$12.98	08/25/2025		M			14,000	(3)	03/01/2026	Common Stock	14,000	$0	0	D

Explanation of Responses:

1. Includes an aggregate of 345 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

2. The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 1, 2026.

3. The option vests in four equal annual installments beginning on March 1, 2017.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.